Thrombotic microangiopathy may be associated with primary cancer or, more likely, with therapeutic regimens, such as gemcitabine or vascular endothelial growth factor (VEGF) inhibitors (such as bevacizumab) [33]. Here, VEGFA is linked to thrombotic microangiopathy.